In addition, the anti-ICOSL monoclonal antibody pre-treatment has a therapeutic effect on joint inflammation in systemic lupus erythematosus patients [35], indicating that ICOS/ICOS-L blockade may be therapeutically beneficial in renal intestinal inflammation. Here, ICOSLG is linked to inflammatory response.